載入...
Exon skipping for Duchenne muscular dystrophy: a systematic review and meta-analysis
BACKGROUND: Exon skipping has been considered a promising therapeutic approach for Duchenne muscular dystrophy (DMD). Eteplirsen received conditional approval in the United States in 2016. To date, no systematic reviews or meta-analyses of randomized controlled trials (RCTs) of exon skipping drugs h...
Na minha lista:
| 發表在: | Orphanet J Rare Dis |
|---|---|
| Main Authors: | , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
BioMed Central
2018
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6003096/ https://ncbi.nlm.nih.gov/pubmed/29907124 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13023-018-0834-2 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|